Introduction
At one-year and six-year post-transrectal ultrasound (TRUS) prostate biopsy two patients (aged 62 and 65) suffered from persistent haematospermia. There had been no haematospermia prior to TRUS biopsy. Both patients also suffered from lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH). Both patients were successfully treated for their BPH with prostatic artery embolisation (PAE). Three months post-procedure the patients reported that their haematospermia had ceased. At 12-month follow-up they had improvements in urodynamics (Qmax), a reduced post-void bladder residual volume of urine, an improvement in International Prostate Symptom Score (IPSS), and improvement in quality of life endpoints (EQ-5D-5L). The prostate volumes had reduced by 42% and 50% (Figures 1 and 2 ) at 12-month follow-up magnetic resonance imaging (MRI) scan.
Discussion
PAE is safe and effective at relieving LUTS and is emerging as a robust alternative to transurethral resection of the prostate (TURP). 1,2 It can provide good improvements in quality of life, urinary flow rate and significantly reduce post-void residual bladder volume. Adenomatousdominant prostates have the greatest reduction in size of the gland and also greatest symptomatic relief. 3 A downside to PAE is the radiation involved in planning and performing the procedure. There is typically no alteration in sexual function and haematuria post-PAE is very rare. Data for the procedure suggest that the medium (1-3 years) and long-term (3-6.5 years) clinical success rates are 81.9% and 76.3% respectively. 2 This suggests that re-treatment might not be necessary in the majority of patients in the medium to long term. However, the rate of re-intervention is currently not well determined. It is likely that the management of BPH will involve a number of strategies including medication, surgery and embolisation with each strategy benefitting certain subgroups of men with BPH. The implementation of alternative treatment strategies in the event of failure of current management will likely also be down to patient/physician choice, which will be dictated by local availability and the side effect profile of each technique.
In the two cases presented here not only was there a reduction in symptoms of BPH but also a cessation in haematospermia. Haematospermia is a difficult condition to treat and also the underlying cause can be difficult to diagnose. Post-TRUS biopsy of the prostate complications such as haematospermia are common. 4 Haematospermia can be distressing and worrisome for men and although many cases resolve spontaneously after four weeks or so those that persist can be particularly distressing. Particulate embolisation using polyvinyl alcohol (PVA) particles delivered via a microcatheter stops the blood flow in the prostate and in the case of BPH causes a reduction in the size of the gland. If there are damaged arteries such as those post-TRUS biopsy, they will also be embolised with particulate matter. It is interesting that in Case 2 it took three months for the haematuria to stop completely. Both patients described a gradual cessation in haematuria with it becoming less frequent (approximately 50% of the time) immediately post-embolisation then after one month it became sporadic before having complete cessation at three months post-procedure. More common causes of prostatic bleeding include peri-rectum bleeding post-TRUS biopsy, BPH, prostatic malignancy and post-surgical bleeding. These cases would also likely be managed successfully with PAE.
PAE is safe and effective in treating BPH and is also useful for the treatment of haematospermia post-TRUS biopsy of the prostate.
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